Thomson finalizes Solucient purchase

Share this article:
Thomson is buying the balance of Solucient from media giant VNU, private equity firm Veronis Suhler Stevenson and healthcare provider alliance VHA.

Thomson snapped up part of the informatics business—that focused on provision of services to payors—last February.

Now the Stamford-based firm has completed its acquisition of Solucient by picking up its analytics business directed at providers. Those businesses will be folded into Thomson's Medstat informatics unit.

Headquartered in Evanston, IL, Solucient boasts a staff of 500 and a secondary office in Ann Arbor, MI, where Medstat is based. Carol Diephuis, EVP at Thomson Medstat, said the firm might consider consolidating offices in the future, but for now, the companies are highly complementary.

“When you think about the combination of expertise and the massive market need in this space, there's growth opportunities for employees of both organizations,” she said. “Solucient helps round out our offering with a lot of information services for hospital managers as well as pharmaceutical companies.”

Before the acquisition, Thomson Health & Scientific employed 4,700. The firm has been moving away from medical publishing and more heavily into healthcare informatics since its divestiture of its Medical Economics business to Advanstar in October 2003.

Thomson continues to publish PDR. Other Thomson assets include its MercuryMD and Micromedix informatics businesses, aimed at healthcare providers, the CenterWatch suite of products and PDA program Clinical Xpert.

Share this article:

Email Newsletters

More in News

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...